Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
Cote, B., Burch, J.D., Asante-Appiah, E., Bayly, C., Bedard, L., Blouin, M., Campeau, L.C., Cauchon, E., Chan, M., Chefson, A., Coulombe, N., Cromlish, W., Debnath, S., Deschenes, D., Dupont-Gaudet, K., Falgueyret, J.P., Forget, R., Gagne, S., Gauvreau, D., Girardin, M., Guiral, S., Langlois, E., Li, C.S., Nguyen, N., Papp, R., Plamondon, S., Roy, A., Roy, S., Seliniotakis, R., St-Onge, M., Ouellet, S., Tawa, P., Truchon, J.F., Vacca, J., Wrona, M., Yan, Y., Ducharme, Y.
Bioorg.Med.Chem.Lett.